Group 1 - The board meeting of Hefei (China) Medical Technology Co., Ltd. was held on August 25, 2025, in a hybrid format at two locations in Shanghai and Beijing, with all six directors present [1][2] - The meeting was legally compliant with relevant laws, regulations, and the company's articles of association, resulting in valid resolutions [1] - The board reviewed and approved all agenda items, with a unanimous vote of 6 in favor, 0 against, and 0 abstentions for the special report on the use of raised funds [2] Group 2 - The special report on the use of raised funds was previously reviewed and approved by the board's audit committee [2] - Detailed information regarding the half-year report and the special report on the use of raised funds is available on the Shanghai Stock Exchange website [1][2]

Group 1 - The core viewpoint of the news is that Madi Technology (603990) has shown a mixed performance in its latest financial results, with a significant drop in revenue but a notable increase in net profit [1] - As of August 25, 2025, Madi Technology's stock closed at 15.36 yuan, with a slight increase of 0.26% and a trading volume of 178,400 hands, amounting to 273 million yuan [1] - The company experienced a net outflow of main funds amounting to 25.92 million yuan, which represents 9.49% of the total transaction amount, indicating a cautious sentiment among investors [1] Group 2 - For the latest financial period ending in mid-2025, Madi Technology reported total operating revenue of 135 million yuan, a decrease of 47.24% year-on-year, while net profit attributable to shareholders was 28.33 million yuan, an increase of 137.11% [1] - The company has a current ratio of 2.509, a quick ratio of 2.388, and a debt-to-asset ratio of 33.30%, indicating a strong liquidity position [1] - Madi Technology, established in 2009 and located in Suzhou, has a registered capital of 3.06 billion yuan and has made investments in 9 companies, participated in 3,041 bidding projects, and holds 84 trademarks and 169 patents [2]

Core Viewpoint - The company has launched the PixelPeel™ safe laser skin rejuvenation treatment to meet the growing demand for safe, effective, and short-recovery skin renewal procedures, initially debuting in North America with plans for global expansion [1] Group 1: Product Details - PixelPeel™ utilizes clinically recognized gold standard laser energy combined with pixel-level precision and Alma's proprietary MotionSync™ technology to ensure a safe, uniform, and controllable treatment process [1] - The treatment effectively improves skin texture, tone, and brightness, making it suitable for both first-time users and those seeking long-term skin maintenance [1] - The solution offers high clinical efficacy with a short recovery period and is applicable to various skin types [1] Group 2: Market Impact - The company believes that PixelPeel™ will provide advanced treatment options that align with current market demands, offering a more convenient and efficient skin care experience for medical institutions and consumers [1] - The comprehensive application of PixelPeel™ in Alma Pixel™ and Alma Hybrid devices aims to expand the market coverage of existing equipment systems, thereby increasing procurement and usage rates [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Sisram Medical Ltd 復䢇醫療科技有限公司* （ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） （股份代號：1696） 自願公告 本公告乃由復銳醫療科技有限公司（「本公司」）自願發佈。 本公司欣然宣佈推出PixelPeel™安全激光煥膚治療方案（「該方案」），旨在滿足對 安全、有效且恢復期短的皮膚煥新療程日益增長的需求，並全面運用在新一代 Alma Pixel™及Alma Hybrid設備系統中。該方案已於北美首發，並計劃逐步推向 全球市場。 於本公告日期，本公司董事會成員包括執行董事劉毅先生及Lior Moshe DAYAN 先生及李家宏先生；非執行董事吳以芳先生及馮蓉麗女士；獨立非執行董事方香 生先生、陳志峰先生、陳怡芳女士及廖啟宇先生。 PixelPeel™運用臨床公認的黃金標準激光能量，結合像素級精準度，並搭載Alma 專利MotionSync™技術，確保治療過程安全、 ...

Core Viewpoint - Suzhou Mediston Medical Technology Co., Ltd. reported a net profit of 28.33 million yuan for the first half of 2025, attributing the increase in profitability to the divestment of its photovoltaic business and a return to its core medical operations, which improved cash flow [1][1]. Group 1: Financial Performance - The company achieved a net profit of 28.33 million yuan in the reporting period [1]. - The improvement in profitability is linked to the completion of the photovoltaic business disposal in January 2025 [1]. Group 2: Business Strategy - Mediston is focusing on the elderly care robot sector, conducting extensive empirical research in nursing homes and hospitals to address emotional, medical, and care needs of the elderly [1][1]. - The company aims to position itself as a supplier of comprehensive smart elderly care solutions and a developer of real application scenarios, differentiating itself from manufacturers that directly produce robots [1]. Group 3: Technological Development - Mediston is developing specialized small models for the elderly care sector based on general large models from companies like Huawei and Alibaba, utilizing clinical medical knowledge bases [1]. - The company is creating a smart elderly care information management system to efficiently operate diverse robotic hardware resources under a centralized command [1]. Group 4: Collaborations and Investments - Mediston has established partnerships with institutions such as the Chinese Academy of Sciences, Huawei, and others to advance research and innovation in elderly care robots and artificial intelligence [1]. - In July 2025, the company increased its stake in its subsidiary, Suzhou Youmai Robot Co., Ltd., to 70%, highlighting its strategic emphasis on the elderly care robot business [1].

天眼查商业履历信息显示，塞力斯医疗科技集团股份有限公司，成立于2004年，位于武汉市，是一家以 从事研究和试验发展为主的企业。企业注册资本19095.2305万人民币，实缴资本3800万人民币。公司法 定代表人为温伟。 金融界消息 截至2025年8月25日收盘，塞力医疗（603716）报收于34.67元，上涨9.99%，换手率 23.65%，成交量45.18万手，成交金额15.37亿元。 资金流向方面，今日主力资金净流入1.87亿元，占比成交额12.17%。其中，超大单净流入2.74亿元、占 成交额17.85%，大单净流出8742.93万元、占成交额5.69%，中单净流出流出11779.00万元、占成交额 7.66%，小单净流出6917.30万元、占成交额4.5%。 塞力医疗最新一期业绩显示，截至2025一季报，公司营业总收入2.87亿元、同比减少40.75%，归属净利 润1432.09万元，同比减少553.66%，扣非净利润2846.33万元，同比减少3228.81%，流动比率1.931、速 动比率1.591、资产负债率58.57%。 通过天眼查大数据分析，塞力斯医疗科技集团股份有限公司共对外投资了70家企 ...

Group 1 - Shanghai Hantong Medical Technology Co., Ltd. recently completed a "Pre-A+ round" financing, raising several tens of millions of RMB, with Shuncheng Capital as the investor [1] - The company was established in 2022, has a registered capital of 5.105429 million RMB, and is primarily engaged in research and experimental development [1] - The company has invested in 5 other enterprises and holds 30 trademark registrations and 26 patents, along with 4 administrative licenses [1] Group 2 - The legal representative of Shanghai Hantong Medical Technology Co., Ltd. is Zhao Wanjin, and the company is located in Shanghai [1] - The shareholders include Zhao Wanjin, Hunan Dacheng Caizhi SME Venture Capital Partnership, Beijing Tongchuang Shared Medical Equity Investment Fund Partnership, Shanghai Hanmai Cheng Medical Technology Partnership, and Shanghai Hanmai Rong Medical Technology Partnership [1]

Summary of Key Points Core Viewpoint - The article highlights the recent stock reduction activities of two A-share listed companies, indicating a cautious sentiment in the market as no companies reported share increases on August 24. Group 1: Company Actions - Juguang Technology's shareholders plan to reduce their holdings by no more than 3.48% of the company's shares [2] - Ailong Technology's controlling shareholder, actual controller, and chairman intend to collectively reduce their holdings by no more than 1.69% of the company's shares [2]

Core Viewpoint - Suzhou Mediston Medical Technology Co., Ltd. (referred to as "Mediston") reported a significant turnaround in its financial performance for the first half of 2025, achieving a net profit of 28.33 million yuan, compared to a loss in the same period last year [1] Financial Performance - The company achieved operating revenue of 135 million yuan and a total profit of 31.14 million yuan during the reporting period [1] - The net profit attributable to shareholders was 28.33 million yuan, marking a return to profitability compared to the previous year [1] Technological Advancements - Mediston completed the domestic software localization and innovation transformation, ensuring compatibility with major domestic hardware and software platforms, meeting national technology requirements [1] - The products are now compatible with Huawei's Kunpeng series servers and support various domestic operating systems, including Tongxin UOS and Kylin [1] - The company has optimized its database compatibility with major domestic databases, ensuring efficient and stable operation in a secure environment [1] AI and Product Development - The company upgraded its anesthesia, critical care, and emergency systems with AI integration and deep fusion with the DeepSeek model [1] - The intelligent doctor assistant module provides clinical decision support, helping doctors formulate precise treatment plans based on patient history and examination data [1] Strategic Collaborations - Mediston's health and wellness robot project has initiated strategic collaborations with multiple medical institutions, focusing on the application of embodied intelligent robots in the health and elderly care sectors [2]

Core Viewpoint - The financial performance of Sichuang Medical (300078) shows significant revenue growth but also highlights challenges in profitability and cash flow management [1][3]. Financial Performance Summary - Total revenue for the first half of 2025 reached 545 million yuan, a year-on-year increase of 37.32% compared to 397 million yuan in 2024 [1]. - The net profit attributable to shareholders was -51.83 million yuan, improving by 76.74% from -22.3 million yuan in the previous year [1]. - The gross profit margin decreased to 8.57%, down 44.26% from 15.38% in the previous year [1]. - The net profit margin improved to -9.85%, a significant increase of 82.68% from -56.86% in 2024 [1]. - The total of selling, administrative, and financial expenses was 86.6 million yuan, accounting for 15.89% of revenue, a decrease of 49.01% year-on-year [1]. Cash Flow and Debt Management - Cash and cash equivalents increased by 151.92% due to increased borrowings [3]. - The company reported a significant reduction in interest-bearing debt, down 68.91% to 339 million yuan [1]. - Operating cash flow showed a decline of 28.0%, attributed to increased tax payments related to property disposals [3]. Operational Insights - Accounts receivable accounted for 50.24% of total revenue, indicating a large volume of outstanding payments [1]. - The company disposed of investment properties, which significantly impacted both revenue and costs, with a revenue contribution of 293.46 million yuan from property disposals [3]. - Research and development expenses decreased by 50.99%, reflecting a reduction in R&D personnel in the medical sector [3]. Historical Performance Context - The company's historical return on invested capital (ROIC) has been weak, with a median of 4% over the past decade and a particularly poor ROIC of -32.19% in 2024 [4]. - The company has experienced four years of losses since its listing, indicating challenges in maintaining profitability [4].